Publication date: Mar 01, 2025
COVID-19 is associated with increased risk of post-acute cardiovascular outcomes. Population-based evidence for long periods of observation is still limited. This population-based cohort study was conducted using data (2020-2021) from the British Columbia COVID-19 Cohort. The exposure of interest was severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, identified through reverse transcription-polymerase chain reaction (RT-PCR) assay. Individuals who tested positive (exposed) on RT-PCR were matched to negative controls (unexposed) on sex, age, and RT-PCR collection date in a 1:4 ratio. Outcomes of interest were incident major adverse cardiovascular events and acute myocardial infarction, identified more than 30 days after RT-PCR collection date. The association between SARS-CoV-2 infection and cardiovascular risk was assessed through multivariable survival models. Population attributable fractions were computed from Cox models. We included 649,320 individuals: 129,864 exposed and 519,456 unexposed. The median duration of follow-up was 260 days; 1,786 events (0. 34%) took place among the unexposed, and 702 (0. 54%) in the exposed. The risk of major adverse cardiovascular events was higher in the exposed (adjusted hazard ratio [aHR] 1. 34; 95% confidence interval [CI], 1. 22-1. 46), with greater risk observed in those who were hospitalized (aHR 3. 81; 95% CI, 3. 12-4. 65) or required intensive care unit admission (aHR 6. 25; 95% CI, 4. 59-8. 52) compared with the unexposed group. The fraction of cardiovascular events attributable to SARS-CoV-2 was 7. 04% (95% CI, 4. 67-9. 41%). Comparable results were observed for acute myocardial infarction. SARS-CoV-2 infection was associated with higher cardiovascular risk, with graded increase across the acute COVID-19 severity, contributing to 7% of incident major adverse cardiovascular events. These findings suggest that long-term monitoring of cardiovascular risk is required in COVID-19 survivors.
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | SARS-CoV-2 Infection |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | MESH | infection |
disease | IDO | assay |
disease | MESH | cardiovascular risk |
disease | MESH | Long Covid |
disease | MESH | Cardiovascular Diseases |
disease | MESH | Myocardial Infarction |